Anna Ractliffe
Stock Analyst at Bank of America Securities
(1.24)
# 3,805
Out of 5,126 analysts
18
Total ratings
50%
Success rate
-2.7%
Average return
Main Sectors:
Stocks Rated by Anna Ractliffe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: FME Fresenius Medical Care AG | Reiterated: Sell | €32.00 | €40.72 | -21.41% | 12 | Nov 4, 2026 | |
| BIT: 1SXP SCHOTT Pharma AG & Co. KGaA | Upgraded: Hold | €27.00 | €24.50 | +10.20% | 1 | Oct 16, 2026 | |
| EPA: BIM bioMérieux S.A. | Upgraded: Hold | €115.00 | €91.65 | +25.48% | 1 | Dec 12, 2025 | |
| LON: RS1 RS Group plc | Upgraded: Buy | 730p | 798p | n/a | 1 | May 13, 2025 | |
| BME: FDR Fluidra, S.A. | Upgraded: Buy | €21.00 → €26.00 | €19.41 | n/a | 2 | Apr 10, 2025 | |
| AMS: LIGHT Signify N.V. | Upgraded: Buy | €29.00 | €15.46 | n/a | 1 | Nov 6, 2024 |
Fresenius Medical Care AG
Nov 4, 2026
Reiterated: Sell
Price Target: €32.00
Current: €40.72
Upside: -21.41%
SCHOTT Pharma AG & Co. KGaA
Oct 16, 2026
Upgraded: Hold
Price Target: €27.00
Current: €24.50
Upside: +10.20%
bioMérieux S.A.
Dec 12, 2025
Upgraded: Hold
Price Target: €115.00
Current: €91.65
Upside: +25.48%
RS Group plc
May 13, 2025
Upgraded: Buy
Price Target: 730p
Current: 798p
Upside: n/a
Fluidra, S.A.
Apr 10, 2025
Upgraded: Buy
Price Target: €21.00 → €26.00
Current: €19.41
Upside: n/a
Signify N.V.
Nov 6, 2024
Upgraded: Buy
Price Target: €29.00
Current: €15.46
Upside: n/a